Nebulized Hypertonic Saline for Bronchiolitis

This study is currently recruiting participants.
Verified June 2012 by Hôpital Armand Trousseau
Sponsor:
Collaborators:
Hôpital Robert Debré
Poissy-Saint Germain Hospital
Hôpital de Versailles
Hôpital Jean Verdier
Information provided by (Responsible Party):
CARBAJAL, Hôpital Armand Trousseau
ClinicalTrials.gov Identifier:
NCT01460524
First received: October 25, 2011
Last updated: June 29, 2012
Last verified: June 2012

October 25, 2011
June 29, 2012
November 2011
May 2013   (final data collection date for primary outcome measure)
Hospitalization rate [ Time Frame: 6 MONTHS ] [ Designated as safety issue: No ]
Comparison of hospitalization rates of infants presenting to the ED with bronchiolitis during the year of use of nebulized hypertonic saline versus the two previous years when nebulized hypertonic saline was not used.
Same as current
Complete list of historical versions of study NCT01460524 on ClinicalTrials.gov Archive Site
  • Length of hospital stay [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Comparison of lenghts of stay of infants hospitalized for bronchiolitis during the year of use of nebulized hypertonic saline in hospitalization wards versus the two previous years when nebulized hypertonic saline was not used.
  • Assessment of 5.85% hypertonic saline tolerance [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    A standardized assessment of the respiratory status will be carried out right before and after each nebulization
Same as current
Not Provided
Not Provided
 
Nebulized Hypertonic Saline for Bronchiolitis
Observational Study on the Use of Hypertonic Saline for the Treatment of Bronchiolitis

In randomized controlled trials, the use of nebulized hypertonic saline in acute bronchiolitis has been reported to improve respiratory distress scores, to reduce length of hospital stay and to show a trend towards lower hospitalization rates.

The investigators aim to verify by an observational study if the rate of hospital admission and the length of hospital stay of infants presenting to the emergency department (ED) with bronchiolitis decreases after the inclusion of 5.85% nebulized hypertonic saline in the treatment strategy of the ED and hospitalization wards.

The investigators will assess the evolution of hospital admission rates and the length of hospital stay in two hospitals that use 5.85% nebulized hypertonic saline for the treatment of bronchiolitis and in two hospital that do not use these nebulizations. If nebulized hypertonic saline is effective in this setting, then the hospitalization rates and length of stay should be lower during the year of hypertonic saline use compared to two previous years when this therapy was not used. These parameters would not be modified in centers that do not use hypertonic saline.

This is a before-after observational study designed to compare the results in terms of hospitalization rate and length of hospital stay between a period when nebulized hypertonic saline was included in the treatment of bronchiolitis in infants versus the two previous years when this therapy was not used in two hospitals. There will not be any randomization.

Physicians have been instructed on the use of hypertonic saline for moderate and severe bronchiolitis in infants but its totally up to them whether to use this nebulization for each particular patient. Two other hospital where nebulized hypertonic saline has never been used and will not be used during the next bronchiolitis epidemics will be the control centers.

The study comprises two periods, one prospective starting on November 2011 and ending in March 2012 and one retrospective including the two previous bronchiolitis epidemics, November 2009-March 2012 and November 2010-March 2011.

During the prospective period a standardized assessment of the respiratory status of each infant will be carried out before and after each hypertonic saline nebulization.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

For the prospective part of the study, all infants up to 1 year of age presenting to the ED for bronchiolitis from November 1st, 2011 to March 30th, 2012 will be included in this observational study. For the retrospective part of the study, data of all infants up to 1 year of age who were seen in the ED for bronchiolitis from November 1st, 2009 and March 30th, 2010 and from November 1st, 2010 and March 30th, 2011 will be analyzed.

Bronchiolitis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
2580
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All infants up to 1 year of age presenting to the ED for bronchiolitis during the study periods.

Exclusion Criteria:

  • Bronchiolitis in infants older than 1 year
Both
up to 1 Year
No
Contact: Ricardo Carbajal, MD, PhD +33 144736487 ricardo.carbajal@trs.aphp.fr
Contact: Emilie Courtois, RN +33 144736451 emilie.courtois@trs.aphp.fr
France
 
NCT01460524
Bronchiolitis-saline
No
CARBAJAL, Hôpital Armand Trousseau
Hôpital Armand Trousseau
  • Hôpital Robert Debré
  • Poissy-Saint Germain Hospital
  • Hôpital de Versailles
  • Hôpital Jean Verdier
Principal Investigator: Ricardo Carbajal, MD, PhD Hôpital Armand Trousseau, Paris
Hôpital Armand Trousseau
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP